SCHEMBL30714693

SCHEMBL30714693

Cn1nc2ccc(OCc3ccccc3)cc2c1C(=O)NC1COCC1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 2/20 0.47
MERTK Q12866 3/20 0.42
AXL P30530 2/20 0.42
NMT1 P30419 3/20 0.40
NMT2 O60551 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HDAC3 O15379 1/20 0.38
APP P05067 1/20 0.38
ACHE P22303 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714618 0.87 SCN9A (0.37) HTR3AMERTKAXLSCN9A
SCHEMBL30714563 0.84 SCN9A (0.35) HTR3ASCN9A
SCHEMBL30714686 0.83 SCN9A (0.40) SCN9A
SCHEMBL30714713 0.79 HTR3A (0.51) HTR3AMAOAMAOB
SCHEMBL26696088 0.78 SRD5A2 (0.50) NMT1NMT2MEN1KMT2ASMN1; SMN2
SCHEMBL30714676 0.78 APOL1 (0.49) HTR3ANMT1MAOAMAOBMMP13
SCHEMBL30714708 0.78 EGLN2 (0.47) HTR3ANMT1NMT2MEN1KMT2A
SCHEMBL30714707 0.77 HTR3A (0.44) HTR3ANMT1NMT2MEN1KMT2A
SCHEMBL30714651 0.77 HTR3A (0.41) HTR3ANMT1NMT2MEN1KMT2A
SCHEMBL26874678 0.77 HTR3A (0.43) HTR3ANMT1MEN1KMT2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 HTR3A 62/4885MERTK 1809/4885AXL 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.